Oncternal therapeutics

Oncternal Therapeutics: Pioneering Cancer Research for Critical Unmet Medical Needs

Oncternal Therapeutics is a clinical-stage oncology company that is dedicated to developing innovative treatments for cancers with critical unmet medical needs. The company has a diverse pipeline of therapies that are designed to target multiple cancer types, and it is committed to translating pioneering areas of cancer research into approved therapies.

The mission of Oncternal Therapeutics is to improve the lives of patients who are suffering from cancer by providing them with effective and safe treatments. The company's approach involves identifying novel targets and pathways that are involved in the development and progression of cancer, and then developing drugs that can selectively inhibit these targets or pathways.

One of the key strengths of Oncternal Therapeutics is its team of experienced scientists, clinicians, and business professionals who have a deep understanding of oncology drug development. The company's leadership team includes experts in drug discovery, preclinical development, clinical trials, regulatory affairs, and commercialization.

Oncternal Therapeutics has several promising drug candidates in its pipeline that are currently being evaluated in clinical trials. These include:

- Cirmtuzumab: A monoclonal antibody that targets ROR1 (Receptor tyrosine kinase-like orphan receptor 1), which is overexpressed on many different types of cancer cells. Cirmtuzumab has shown promising results in early-stage clinical trials for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

- TK216: A small molecule inhibitor that targets ETS transcription factors, which play a critical role in the growth and survival of Ewing sarcoma tumors. TK216 has shown preclinical activity against Ewing sarcoma cells both alone or when combined with chemotherapy agents.

- ROR1 CAR-T: Chimeric antigen receptor T-cell therapy targeting ROR1-expressing cancers such as CLL/MCL/WM and solid tumors.

- B-Cell Maturation Antigen (BCMA) CAR-T: Chimeric antigen receptor T-cell therapy targeting BCMA-expressing cancers such as multiple myeloma.

Oncternal Therapeutics is also actively exploring other potential drug targets and pathways that could lead to the development of new cancer therapies. The company's research efforts are focused on areas such as immuno-oncology, epigenetics, and tumor metabolism.

In addition to its drug development programs, Oncternal Therapeutics is committed to building strong partnerships with academic institutions, biotech companies, and pharmaceutical companies. These collaborations enable the company to access cutting-edge technologies and expertise that can accelerate its drug discovery efforts.

Overall, Oncternal Therapeutics is a dynamic oncology company that is making significant strides in the development of innovative cancer therapies. With a strong pipeline of drug candidates and a talented team of experts, the company is well-positioned to make a meaningful impact on the lives of patients who are battling cancer.